Kiora Pharmaceuticals (KPRX) News Today → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free KPRX Stock Alerts $0.51 +0.02 (+4.08%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11 at 6:58 PM | markets.businessinsider.comBuy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical TrialsMay 11 at 3:20 AM | americanbankingnews.comKiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Up 1.4%May 10 at 3:26 PM | investorplace.comKPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024May 10 at 10:17 AM | finanznachrichten.deKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal DiseaseMarch 25, 2024 | msn.comKiora Pharmaceuticals reports FY resultsFebruary 9, 2024 | markets.businessinsider.comKiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial ResultsFebruary 9, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To KnowFebruary 1, 2024 | msn.comWhat's Going On With Kiora Pharmaceuticals Stock?February 1, 2024 | benzinga.comWhy Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketFebruary 1, 2024 | msn.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?January 31, 2024 | msn.comKiora stock soars after hours on deal with Thea Open InnovationJanuary 31, 2024 | finance.yahoo.comKiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial RoyaltiesJanuary 31, 2024 | finance.yahoo.comKiora Pharmaceuticals Announces Private Placement of up to Approximately $45 MillionJanuary 31, 2024 | marketbeat.comTrading was temporarily halted for "KPRX" at 05:01 PM with a stated reason of "News pending."January 9, 2024 | morningstar.comKiora Pharmaceuticals Inc KPRXNovember 17, 2023 | finance.yahoo.comBreaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301November 11, 2023 | benzinga.comKiora Pharmaceuticals Stock (NASDAQ:KPRX) Earnings Dates and Earning CallsNovember 9, 2023 | msn.comKiora Pharmaceuticals reports Q3 resultsNovember 9, 2023 | finance.yahoo.comKiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis PigmentosaNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)November 6, 2023 | markets.businessinsider.comAnalyst Expectations for Kiora Pharmaceuticals's FutureNovember 4, 2023 | finance.yahoo.comAAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis PigmentosaOctober 16, 2023 | finance.yahoo.comKiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor ConferenceOctober 3, 2023 | finance.yahoo.comKiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis PigmentosaSeptember 21, 2023 | finance.yahoo.comKiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 YearsSeptember 18, 2023 | finance.yahoo.comKiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis PigmentosaSeptember 14, 2023 | finance.yahoo.comKiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis PigmentosaSeptember 1, 2023 | finance.yahoo.comKiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27August 29, 2023 | finance.yahoo.comKiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal DiseasesAugust 24, 2023 | finance.yahoo.comIs Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation AnalysisAugust 23, 2023 | marketwatch.comKiora Pharmaceuticals Shares Up 18% on Patents Covering Ocular Delivery of MoleculesAugust 23, 2023 | markets.businessinsider.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Up 11% Today?August 23, 2023 | finance.yahoo.comKiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious UveitisAugust 22, 2023 | finance.yahoo.comKiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness ProgramAugust 16, 2023 | finance.yahoo.comKiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceAugust 8, 2023 | finance.yahoo.comKiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development ProgressAugust 3, 2023 | finance.yahoo.comKiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia TreatmentAugust 1, 2023 | finance.yahoo.comBiotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of DirectorsJuly 21, 2023 | investorplace.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today?July 5, 2023 | finanznachrichten.deKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic DiseaseJuly 5, 2023 | finance.yahoo.comKiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic DiseaseJune 22, 2023 | marketwatch.com8-K: KIORA PHARMACEUTICALS INCJune 20, 2023 | finance.yahoo.comLife Science Investor Forum Agenda Announced for June 22ndJune 15, 2023 | finanznachrichten.deKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201June 15, 2023 | finance.yahoo.comKiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201June 14, 2023 | finance.yahoo.comKiora Pharmaceuticals to Present at Upcoming Investor ConferencesJune 6, 2023 | finance.yahoo.comKiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionJune 2, 2023 | baystreet.caKiora Heralds Public OfferingJune 2, 2023 | investorplace.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Down 49% Today?May 9, 2023 | msn.comRecap: Kiora Pharmaceuticals Q1 Earnings Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address [URGENT] DO NOT Touch These AI Stocks! (Ad)Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over? Click here for our #1 AI Stock for 2024 and Beyond KPRX Media Mentions By Week KPRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPRX News Sentiment▼0.000.58▲Average Medical News Sentiment KPRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPRX Articles This Week▼71▲KPRX Articles Average Week Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Monopar Therapeutics News Today Purple Biotech News Today RedHill Biopharma News Today Avalo Therapeutics News Today Pieris Pharmaceuticals News Today Imunon News Today FSD Pharma News Today Edesa Biotech News Today Elevai Labs News Today Akari Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPRX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
